- Home
- VOXR vs CRDF Comparison
VOXR vs CRDF Comparison
Compare VOXR & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VOXR
- CRDF
- Stock Information
- Founded
- VOXR 2014
- CRDF 1999
- Country
- VOXR United States
- CRDF United States
- Employees
- VOXR N/A
- CRDF N/A
- Industry
- VOXR Precious Metals
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VOXR Basic Materials
- CRDF Health Care
- Exchange
- VOXR Nasdaq
- CRDF Nasdaq
- Market Cap
- VOXR 168.0M
- CRDF 169.6M
- IPO Year
- VOXR N/A
- CRDF N/A
- Fundamental
- Price
- VOXR $3.65
- CRDF $3.79
- Analyst Decision
- VOXR
- CRDF Strong Buy
- Analyst Count
- VOXR 0
- CRDF 4
- Target Price
- VOXR N/A
- CRDF $12.25
- AVG Volume (30 Days)
- VOXR 326.1K
- CRDF 1.0M
- Earning Date
- VOXR 08-06-2025
- CRDF 05-08-2025
- Dividend Yield
- VOXR 1.39%
- CRDF N/A
- EPS Growth
- VOXR N/A
- CRDF N/A
- EPS
- VOXR N/A
- CRDF N/A
- Revenue
- VOXR $10,845,445.00
- CRDF $587,000.00
- Revenue This Year
- VOXR $16.51
- CRDF N/A
- Revenue Next Year
- VOXR $4.60
- CRDF N/A
- P/E Ratio
- VOXR N/A
- CRDF N/A
- Revenue Growth
- VOXR N/A
- CRDF N/A
- 52 Week Low
- VOXR $2.21
- CRDF $2.01
- 52 Week High
- VOXR $3.79
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- VOXR 58.95
- CRDF 61.40
- Support Level
- VOXR $3.47
- CRDF $2.81
- Resistance Level
- VOXR $3.70
- CRDF $4.38
- Average True Range (ATR)
- VOXR 0.20
- CRDF 0.30
- MACD
- VOXR -0.00
- CRDF 0.07
- Stochastic Oscillator
- VOXR 73.83
- CRDF 62.42
About VOXR Vox Royalty Corp.
Vox Royalty Corp is a returns-focused mining royalty company with a portfolio of royalties and streams spanning eight jurisdictions. It has built intellectual property, a technically focused transactional team, and a sourcing network which has allowed Vox to target the highest returns on royalty acquisitions in the mining royalty sector. The company geographically operates Australia, Nigeria, USA, and Brazil.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.